

OXIS International, Inc. announces Changes in Management Team

BEVERLY HILLS, Calif., Nov. 20, 2014 -- Oxis International, Inc. (OXIS) (OXI.PA) announced today the resignation of Ken Eaton, the election of Anthony J. Cataldo as Chief Executive Officer, and Steven Weldon as President.

Effective November 19, 2014, Ken Eaton resigned his positions as Chief Executive Officer and member of the Board of Directors of Oxis International, Inc. to pursue new opportunities.

Mr. Anthony J. Cataldo has been named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo will continue to serve as Chairman of Oxis International, Inc. and President of Oxis Biotech, Inc. a wholly owned subsidiary of Oxis International, Inc. Mr. Cataldo joined the Oxis International Board of Directors in July of 2014. From February 2011 to June 2013 Mr. Cataldo served as Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc., (LBIO). Mr. Cataldo created Lion/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector with MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.

Mr. Steven Weldon joined the Oxis International, Inc. team as a member of the Board of Directors in September 2014. He was appointed Chief Financial Officer in November 2014. Mr. Weldon was elected President of Oxis International, Inc November 19, 2014. Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over 15 years of financial and accounting experience with public and private companies. Steven received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor. Mr. Weldon has years of experience as board member, Chief Financial Officer and Chief Executive Officer of publicly traded companies.

Oxis Chairman/CEO Tony Cataldo said, "We appreciate all of the efforts of Mr. Eaton on behalf of the shareholders of Oxis International, Inc. We wish him the very best of success in his new business endeavors. Steven and I look forward to taking the management lead from here and moving Oxis International and Oxis Biotech forward at warp speed."

OXIS President Steven Weldon stated, "I am very excited to be part of the team at Oxis. I believe we are making great strides in acquiring and developing assets that will prove very valuable to our shareholders."

Contact:
Jon Barkman
Riverview Capital Enterprises
866-845-0105

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Oxis International, Inc.